David E. Gilham

21c Consultancy (United Kingdom) — United Kingdom

Medicine · Health Sciences

40h-index4.9kcitations134works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(112), Immune Cell Function and Interaction(55), Immunotherapy and Immune Responses(32), T-cell and B-cell Immunology(20), Virus-based gene therapy research(20)

Publications134 total

In Remembrance of Professor Zelig Eshhar: <i>A Life Committed to CAR-T</i>
Human Gene Therapy·2025Open Access
Evidence of clinical efficacy of a first generation CD19 CAR T cell in B cell malignancies
eJHaem·2023· 6 citedOpen Access
Table S3 from Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
2023Open Access
Table S2 from Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
2023Open Access
Data from Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
2023Open Access
Table S1 from Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
2023Open Access
Table S2 from Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
2023Open Access
Data from Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
2023Open Access
Table S3 from Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
2023Open Access
Table S1 from Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
2023Open Access
Figure S1 from Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
2023Open Access
Figure S1 from Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
2023Open Access
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial
The Lancet Haematology·2023· 84 citedOpen Access
Immunicy-1: Targeting BCMA with Cyad-211 to Establish Proof of Concept of an shRNA-Based Allogeneic CAR T Cell Therapy Platform
Blood·2021· 23 cited
Co-Expression of an shRNA Targeting MICA/Micb Improves the Clinical Activity of a NKG2D-Based CAR T in Patients with Relapsed / Refractory AML/MDS
Blood·2021· 10 cited
146 Evolving Mutliplexed shRNA to generate tailored CAR T cell therapy
Regular and Young Investigator Award Abstracts·2021· 1 citedOpen Access
107 Armoring NKG2D CAR T cells with IL-18 improves in vivo anti-tumor activity
Regular and Young Investigator Award Abstracts·2021· 5 citedOpen Access
407 A phase 1b KEYNOTE-B79 trial evaluating non-gene edited allogeneic CAR T-cells, CYAD-101, post FOLFOX preconditioning, followed by pembrolizumab, in refractory metastatic colorectal cancer patients
Regular and Young Investigator Award Abstracts·2021Open Access
Enhancing preclinical predictivity in I-O: what is going wrong between preclinical in vitro/in vivo and clinical settings?
Immuno Oncology Insights·2021
Updated data from alloSHRINK phase I first-in-human study evaluating CYAD-101, an innovative non-gene edited allogeneic CAR-T in mCRC.
Journal of Clinical Oncology·2021· 41 cited
page 1 of 7Next →

Frequent Co-authors

Robert E. Hawkins(29), Eleanor J. Cheadle(11), Dominic G. Rothwell(7), Frédéric Lehmann(7), John S. Bridgeman(6), Caroline Lonez(6), Peter L. Stern(5), Hinrich Abken(5), Victoria Sheard(5), Н. А. Кириллова(4), Richard W. Griffiths(4), Erik Alcantar-Orozco(4), Ryan D. Guest(3), Joana Murad(3), Charles L. Sentman(3), Eyad Elkord(3), Reno Debets(3), Milena Kalaitsidou(3), Vania Baldan(3), Andreas Hombach(3)